Gilead Sciences, Inc.
Financials
Valuation Metrics
Gilead Sciences, Inc.'s Market Cap is $162.83B. At end of 2025 it was $152.44B. Ranked #96 of 3,111 in US market (top 3%), #35 of 1,445 on NASDAQ (top 2%), #9 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $162.83B | US#96/3,111 Sec#9/269 |
| Revenue | $29.73B | US#224/3,111 Sec#14/269 |
| Net Income | $9.22B | US#70/3,111 Sec#6/269 |
| Total Assets | $56.28B | US#303/3,111 Sec#14/269 |
| Net Assets | $23.52B | US#214/3,111 Sec#13/269 |
| Employees | 17,000 | US#416/3,111 Sec#10/269 |
| Value | ||
| P/E | 17.67x | US#865/3,111 Sec#33/269 |
| P/B | 6.92x | US#2,414/3,111 Sec#170/269 |
| PEG | 0.33x | US#430/3,111 Sec#19/269 |
| P/S | 5.48x | US#2,339/3,111 Sec#88/269 |
| EV/EBITDA | 12.65x | US#1,156/3,111 Sec#38/269 |
| FCF Yield | 6.28% | US#1,027/3,111 Sec#40/269 |
| Profitability | ||
| ROE | 39.19% | US#171/3,111 Sec#18/269 |
| ROA | 16.38% | US#171/3,111 Sec#25/269 |
| Op. Margin | 38.26% | US#256/3,111 Sec#16/269 |
| Revenue Growth | 4.39% | US#1,808/3,111 Sec#110/269 |
| Earnings Growth | 53.69% | US#532/3,111 Sec#26/269 |
| Financial Health | ||
| Debt Ratio | 139.69% | US#1,425/3,111 Sec#183/269 |
| Total Debt | $22.17B | US#216/3,111 Sec#14/269 |
| FCF | $10.23B | US#71/3,111 Sec#7/269 |
| Cash | $7.63B | US#141/3,111 Sec#5/269 |
| Current Ratio | 1.97x | US#1,270/3,111 Sec#231/269 |
| Net Debt/EBITDA | 1.04x | US#1,009/3,111 Sec#49/269 |
| Dividend | ||
| Div. Yield | 2.48% | US#760/3,111 Sec#14/269 |
| Div. Growth | 2.42% | US#1,023/3,111 Sec#18/269 |
| Performance | ||
| 1Y Return | 17.45% | US#1,505/3,111 Sec#169/269 |
| 1M Return | -0.09% | US#1,073/3,111 Sec#73/269 |
| From 52W High | -16.62% | US#1,480/3,111 Sec#100/269 |
| 1Y MDD | -22.03% | US#829/3,111 Sec#42/269 |
| Trading | ||
| Volume | 6,876,978 shares | US#374/3,111 Sec#24/269 |
| Trading Value | $898M | US#154/3,111 Sec#9/269 |
| Per Share | ||
| EPS | $6.85 | US#439/3,111 Sec#15/269 |
| BPS | $18.21 | US#1,295/3,111 Sec#37/269 |
Company Info
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.